Read if you want one stock you can retire on

[brucefan]

Predictive Laboratories Announces Research Collaboration with the Preeclampsia Foundation

Collaboration to expand the study of genetic factors contributing to preeclampsia and support Predictive Laboratories’ development of personalized products to detect preeclampsia risk before and during pregnancy

Email Print Friendly Share
July 31, 2019 12:25 ET | Source: Predictive Technology Group, Inc.

SALT LAKE CITY, July 31, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent precision therapeutic intervention, announces that its wholly owned subsidiary Predictive Laboratories has entered into a research collaboration with the Preeclampsia Foundation to expand the study of genetic factors associated with preeclampsia. The study will advance the Preeclampsia Foundation’s database of collected preeclampsia medical information and will be utilized by Predictive Laboratories to develop a proprietary test for the early detection of women at risk for preeclampsia.
​

Preeclampsia affects 5-8%, or approximately 300,000, pregnancies every year in the United States, sometimes causing severe adverse maternal and fetal outcomes, including organ failure, massive blood loss, permanent disability or even death. Globally, preeclampsia is a leading cause of pregnancy complications, preterm births and related disabilities. The deaths of approximately 76,000 mothers and 500,000 babies annually are attributable to preeclampsia. Healthcare providers, even in medically advanced countries, are hampered by imprecise diagnostic tools.
The Preeclampsia Registry, a key program of the Preeclampsia Foundation’s research mission, is a patient registry that collects paired medical information and biological samples. Using established Institutional Review Board-approved protocols, Predictive Laboratories and the Preeclampsia Foundation will request samples from more than 2,500 existing and new registry participants for sequencing analysis. Predictive Laboratories has been granted a period of exclusive access to research data resulting from these new samples enrolled in the Preeclampsia Registry, after which samples and sequencing data will be available to other investigators for future research.
“The Preeclampsia Foundation created an empowered community of patients and experts with a diverse array of resources, support and advocacy to help women have the best possible outcomes from their pregnancies,” said Bradley Robinson, CEO of Predictive Technology Group. “We look forward to enhancing our partnership, helping to grow the Preeclampsia Registry resource and developing innovative and effective products aimed at the early detection and treatment of this devastating medical condition.”
This collaboration complements and extends ongoing preeclampsia research initiatives at Predictive Laboratories. Over 20,000 DNA samples from Predictive's biorepository relating to preeclampsia and associated obstetric syndromes are being analyzed. Predictive Laboratories’ pending patent applications relating to predictive genetic markers of preeclampsia were acquired through its acquisition of Taueret Laboratories, which was completed in March 2019. Prior to acquisition, the Taueret Laboratories team had a long history of collaboration with the Preeclampsia Foundation and invested significant resources towards genotyping and sequencing thousands of samples during discovery work. The combination of knowledge and resources under the Predictive Laboratories subsidiary represents a strong pipeline for developing novel DNA based products.
“We envision a world where preeclampsia no longer threatens the lives of mothers and their babies,” said Eleni Tsigas, CEO of the Preeclampsia Foundation. “In addition to a diagnostic test Predictive Laboratories may develop, this infusion of genomic data to our already robust registry accelerates our research agenda and brings us closer to making our vision a reality.”
About the Preeclampsia Foundation
Established in 2000, the Preeclampsia Foundation is the only 501(c)(3) not-for-profit patient advocacy organization representing the 5-8% of pregnant women and their babies who are affected by life-threatening hypertensive disorders of pregnancy, such as preeclampsia, eclampsia, and HELLP syndrome. The Foundation is advised by a medical board comprised of top medical and scientific experts and works collaboratively with many other stakeholders to achieve its mission of improving the outcomes of hypertensive disorders of pregnancy by educating, supporting and engaging the community, improving healthcare practices, and finding a cure. Additional information is available at Preeclampsia.org and Preeclampsiaregistry.org.
About Predictive Laboratories, Inc.
Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a high complexity molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). The group recently launched its novel test for women experiencing infertility, ARTguide™, to selected collaborators. ARTguide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other genetic conditions. The test is expected to change the way that Advanced Reproductive Technologies (ART), such as in vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contact:
For more information, visit www.predtechgroup.com or contact Investor Relations:
Investor Contact
LHA Investor Relations
Jody Cain jcain@lhai.com
Kevin Mc Cabe kmccabe@lhai.com
310-691-7100

 

[brucefan]

 

[RapStar]

I was curious as to what today's catalyst for movement was. Thanks Bruce.

 

[MattyMatt]

Bill Gates needs a couple millie shares of PRED...LOL

 

[RapStar]

Bill Gates needs a couple millie shares of PRED...LOL

:aktion033:aktion033:aktion033:aktion033:aktion033

 

[brucefan]

Predictive Laboratories to Present New Endometriosis Discoveries in Three Presentations at Leading Scientific Conference Focused on Human Infertility

American Society of Reproductive Medicine selects findings through scientific peer-review process for presentations at the 75th ASRM Scientific Congress & Expo in October

Email Print Friendly Share
August 02, 2019 09:15 ET | Source: Predictive Technology Group, Inc.

SALT LAKE CITY, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc. (OTC PINK: PRED), announces the presentation of new genetic findings in endometriosis at the 75[SUP]th[/SUP] American Society of Reproductive Medicine (ASRM) Scientific Congress & Expo being held October 12-16, 2019 in Philadelphia. The new findings will be presented by Predictive Laboratories’ scientific team. Predictive Technology Group is a leader in the use of data analytics for disease identification and subsequent precision therapeutic intervention.
​

Three scientific presentations (two oral and one poster) highlighting recent discoveries by Predictive Laboratories were selected through ASRM’s scientific peer-review process. The presentations will focus on several features of endometriosis, including genetic mechanisms underlying the disorder, potential disease gene interactions, and the mechanisms through which some benign endometriosis lesions might become cancerous. The content of these presentations is embargoed until data are presented at the conference. Patent applications have been filed around these new discoveries adding to the Company’s robust endometriosis patent portfolio.
Endometriosis affects more than 10 million women in the United States. It occurs when tissue similar to the lining of the uterus (womb) appears in other parts of the body, most commonly in the pelvis. Monthly bleeding and inflammation caused by these lesions may severely impact a woman’s quality of life. Some affected women experience severe pain, others infertility, others have problems with their menstrual periods, and some have no symptoms at all. Treatment may involve hormonal suppression or surgical destruction of the abnormal tissue.
“We are very pleased with the acceptance of these presentations by ASRM and to be presenting this important data to the thousands of researchers and physicians attending the ASRM meetings,” said Bradley Robinson, CEO of Predictive Technology Group. “Most importantly we look forward to these discoveries being applied in clinical settings to reduce the suffering of millions of women around the world and aiding to eliminate or reduce the related complications of this debilitating disease.
“We look forward to announcing these data following the presentations at ASRM meeting,” he added. “I’m delighted with the commitment of our scientific team and its dedication in continuing to expand the understanding of endometriosis.”
The Company’s population genetics research underlies its novel ARTGuide™ test, a first-of-its-kind non-invasive diagnostic test for endometriosis and other genetic causes of infertility currently launched to select collaborators by Predictive Laboratories.
ASRM is an international and multi-disciplinary organization devoted to advancing knowledge and expertise in reproductive medicine and biology, with a particular focus on human infertility.
About Predictive Laboratories, Inc.
Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a high complexity molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). The group recently launched its novel test for women experiencing infertility, ARTguide™, to selected collaborators. ARTguide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other genetic conditions. The test is expected to change the way that Advanced Reproductive Technologies (ART), such as in vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contacts:
For more information, visit www.predtechgroup.com or contact Investor Relations:
Investor Contact
LHA Investor Relations
Jody Cain jcain@lhai.com
Kevin Mc Cabe kmccabe@lhai.com
310-691-7100

Related Articles​

 

[RapStar]

Thanks for always keeping us up to speed, Bruce.

 

[brucefan]

Predictive Technology Group Names Industry Veteran Dr. E. Robert Wassman Co-Laboratory Director of Predictive Laboratories

Dr. Wassman brings 35 years of genetics diagnostic and personalized medicine experience, and significant expertise to lead the cytogenetics section of Predictive Laboratories

Email Print Friendly Share
August 06, 2019 09:15 ET | Source: Predictive Technology Group, Inc.
photo-release

Dr. E. Robert Wassman




Dr. E. Robert Wassman named Co-Laboratory Director of Predictive Laboratories
Predictive Technology Group, Inc.

SALT LAKE CITY, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces the appointment of E. Robert Wassman, M.D. as Co-Laboratory Director of Predictive Laboratories.
​

Dr. Wassman has been pioneering the introduction of genetic testing and personalized medicine for over 35 years. Throughout his career, he has focused on the translation and delivery of cutting-edge diagnostic technology to clinical services in the areas of reproductive medicine, rare cell/non-invasive diagnostics, and next-generation DNA sequencing. He brings Predictive Laboratories critical expertise in reproductive genetics, cancer and companion diagnostics, and neurodevelopmental disabilities including autism. Dr. Wassman is a graduate of Yale University and Albany Medical College and he is Board Certified in Pediatrics and Medical Genetics.
Dr. Wassman previously served as Chief Medical Officer for multiple companies in the genetic testing space including Genzyme Genetics, Lineagen, Rosetta Genomics, Generation Health, Helicos Biosciences, Good Start Genetics, Celula, Ambry Genetics and Alfigen. He co-founded several successful ventures and served as a consultant to a wide variety of entities ranging from large to small clinical laboratories, IVD and biotech companies, investment groups, regulatory agencies, payers and legal firms.
In addition to clinical and technical expertise, Dr. Wassman has laboratory and general operational, business development, medical affairs/marketing and sales experience in the U.S., Europe, Japan and China. He has formal training and both public and private sector experience in reimbursement and managed care. Dr. Wassman currently serves on the Board of Directors and Scientific Advisory Board of the TESS Foundation, a non-profit focused on treatments for epilepsy and symptoms of SLC13A5 epileptic encephalopathy.
“We are delighted that Dr. Wassman is joining our outstanding team at Predictive Laboratories,” said Bradley Robinson, CEO of Predictive Technology Group. “Dr. Wassman’s strategic insights, deep scientific and medical knowledge, and quick study abilities have enabled him to play a pivotal role in numerous firsts in reproductive genetics including expanded maternal serum screening, the first nationwide Pre-Implantation Genetic (PGD) test, and the first commercially successful clinical NGS-based testing for carrier screening in IVF clinics. We welcome him to Predictive Laboratories and look forward to his contributions as we expand our genetic-based diagnostics.”
About Predictive Laboratories, Inc.
Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a high complexity molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). The group recently launched its novel test for women experiencing infertility, ARTguide™, to selected collaborators. ARTguide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other genetic conditions. The test is expected to change the way that Assisted Reproductive Technologies (ART), such as in vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contacts:
For more information, visit www.predtechgroup.com or contact Investor Relations:
Investor Contact
LHA Investor Relations
Jody Cain jcain@lhai.com
Kevin Mc Cabe kmccabe@lhai.com
310-691-7100
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1e245367-5716-4ca6-994c-9033c329747a

 

[MattyMatt]

Hopefully it's about time to leave the station again...

Nice buys and little pop this morning. Steady climb the past few days...

 

[brucefan]

Predictive Technology Group Announces Launch of PGxPLUS+™ Pharmacogenomic Test and Reaches Clinical Study Enrollment Milestone

Enrollment reaches 350 patients for IRB-approved study focused on chronic pain

Email Print Friendly Share
August 09, 2019 09:15 ET | Source: Predictive Technology Group, Inc.

SALT LAKE CITY, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapies, announces that its wholly owned subsidiary Predictive Laboratories, Inc. has commercially launched PGxPLUS+, a pharmacogenomic test panel being marketed to pain clinics for patients with chronic pain. PGxPLUS+ evaluates genetic factors that play a major role in an individual’s response to medications. In parallel, Predictive Laboratories has reached a milestone of enrolling 350 patients with chronic pain into an Investigational Review Board-approved clinical study aimed at providing additional insight into the mechanisms of chronic pain and responses to pain therapies.
​

Predictive Technology Group is tackling chronic pain and the opioid crisis on multiple fronts. Predictive has already developed and in-licensed important prognostic DNA tests and novel treatments for osteoarthritis, lumbar disc disease, endometriosis, and other conditions causing chronic pain. In 2016, the Institute of Medicine estimated that up to one-third of the U.S. population lives with ongoing pain. Chronic pain is often triggered by one of these common conditions, and over time can develop into a chronic pain syndrome, which is a disease itself.
The PGxPLUS+ panel is one of the most comprehensive pharmacogenetic tests available on the market. Predictive’s test evaluates 112 genetic variants across 38 genes that affect the metabolism of over 150 common medications, including pain medications. More than 90% of the population has one or more gene variants that affect the efficacy or safety of prescription drugs. Variation in drug metabolism is largely determined by an individual’s genetic profile, blood levels of a drug may vary up to 1,000-fold in similar patients taking identical doses of the same drug. Pharmacogenomics is the study of the role of our genome in drug responses.
Dr. Bryt Christensen, M.D., a pain specialist, reports, “The PGxPLUS+ pharmacogenetic test has been very helpful in my day-to-day practice. The results give insights into why some patients are not responding to medications as expected. With the help of these test results, I have been able to start or switch medications for patients more successfully. The PGxPLUS+ test helps me avoid prescribing medications that a patient won’t metabolize well, leading to better and more personalized patient care.”
One-third of patients taking long-term opioid therapy for non-cancer chronic pain either find their medication to be ineffective or they do not tolerate the side effects of the treatment. In the clinical study, Predictive is testing patients who are taking high doses of opioids [≥50 morphine milligram equivalents (MME)/day] for genetic variants responsible for their underlying disease, their metabolism of opioids, their intrinsic pain thresholds, and any genetic predisposition to opioid addiction. Predictive plans to develop more comprehensive treatment guidelines for pain based on predictive genetic markers.
“The ability to effectively treat individuals in pain represents a significant market opportunity and of even greater importance it serves an obligation of society to alleviate the current pain and suffering of an individual in a safer and more effective manner,” said Bradley Robinson, CEO of Predictive Technology Group. “Our Company is both identifying the most effective ways to treat pain at a personalized level and working to understand the underlying cause of diseases like osteoarthritis, lumbar disc disease and endometriosis to treat or prevent the root cause of the pain. We are pleased to add the PGxPLUS+ test to our portfolio of regenerative medicine and diagnostic products focused on treating chronic pain diseases.”
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contacts:
For more information, visit www.predtechgroup.com or contact Investor Relations:
Investor Contact
LHA Investor Relations
Jody Cain jcain@lhai.com
Kevin Mc Cabe kmccabe@lhai.com
310-691-7100

 

[MattyMatt]

Great news, however, the only news that seems to matter right now is NASDAQ news.

 

[Bozzie]

What is the status or changes of a listing on a bigger board at this point...?

 

[MattyMatt]

What is the status or changes of a listing on a bigger board at this point...?

Anyday now it seems, but idk, you tell me...

 

[brucefan]

just fyi, the crooks put another tweet this morning, with more obvious bullshit . They are getting desperate now

My guess, next week we hear on NASDQ

 

[brucefan]

Predictive Technology Group Inc (OTCMKTS: PRED): A Buy On Improving Fundamentals

ByJim Bloom
Posted on August 13, 2019

TWEET
SARE
EMAIL
COMMENTS
Predictive Technology Group Inc (OTCMKTS: PRED) is an exciting bounce back play after a steep pullback from all-time highs. While the stock has taken a significant hit in recent months, one cannot dispute the company’s growth metrics and long-term prospects. The deep pullback presented an exciting buy opportunity as we discussed in our last article. Many of our subscribers went long at $1.50 after getting our emails on PRED.
PREDICTIVE TECHNOLOGY PRICE ANALYSIS

The $1.50 is the immediate support level from where Predictive Technology is well supported for further upside action. The unveiling of a pharmacogenomic test panel targeting pain clinics is one of the catalysts fuelling the upward momentum. In addition, the company is fresh from inking a strategic partnership with the Preeclampsia Foundation as it moves to expand the study of genetic factors.
Recent price action activity indicates that Predictive Technology might as well have hit bottom at the $1.50 level and due for a correction higher. A flurry of positive developments on the strengthening of the company’s product line should continue to trigger renewed investor interest in the stock.

Daily Chart PRED

Above the $3 mark, the stock should make a run for the $5 a share mark, seen as the immediate resistance level standing in the way of further upside action. A close above the $3 a share level should bring to an end the bearish run that PRED succumbed in July.
ABOUT PREDICTIVE TECHNOLOGY

Predictive technology bills itself as a media technology company seeking to revolutionize patient care through predictive data analytics. The company is engaged in the development of gene-based diagnostics and therapeutics, targeting endometriosis, Scoliosis, and degenerative disc disease.
CHRONIC PAIN OPPORTUNITY

While Predictive Technology has shed a significant amount of market share after peaking in June, the future can only be bright given the progress made in developing gene-based diagnostics. The leader in data analytics for disease identification is fresh from unveiling game-changing pharmacogenomics test, poised to expand its footprint into the pain management market.
The new pain test panel is designed to evaluate genetic factors that influence people’s response to medications. Predictive Technology, through its subsidiary Predictive Laboratories, has enrolled 350 patients as part of an Investigational Review Board approved clinical trials.
PGxPLUS+test has the potential to be agama changer as a long term opioid therapy for chronic pain

“The ability to effectively treat individuals in pain represents a significant market opportunity, and of even greater importance it serves an obligation of society to alleviate the current pain and suffering of an individual more safely and effectively,” said CEO Bradley Robinson.
​

PREECLAMPSIA FOUNDATION PARTNERSHIP

Separately, Predictive Technology has entered into a research collaboration with the Preeclampsia Foundation. As part of the partnership, the two are toe expand the study of genetic factors that trigger preeclampsia.
The condition affects about 300,000 pregnancies every year, resulting in severe maternal and fetal outcomes. Organ failure, massive blood loss, and permanent disability are some of the outcomes associated with medical conditions.
By studying the genetic factors associated with the condition, Predictive Technology and Preeclampsia hope to advance preeclampsia database. Predictive Laboratories will, in return, leverage the database to come up with a proprietary test for early detection, in women at risk of preeclampsia.
ROBUST REVENUE GROWTH

Recent developments underscore a company that has made huge strides in building a strong infrastructure for enhancing development and commercialization of proprietary genetic-based diagnostics.
The future can only be bright, especially on the opening of a state of the art production laboratory and R&D facility. As it stands, Predictive Technology remains well positioned to meet production and sales needs of human cell and tissue products for regenerative medicine.
A tenth consecutive quarter of revenue growth in the third quarter of 2019, underscores a company in a phase of robust growth. Revenue for the first nine months of fiscal 2019 exceeded the $30 million mark. Revenue growth stems from continued growth in sales volume as well as strong demand for human cell and tissue products.
BOTTOM LINE

True to the adage, buy low sell high. The steep pullback presented an opportunity to bet on Predictive Technology long-term prospects and growth metrics. We still believe PRED will see new highs later on this year.
Market sentiments have started to pick up some steam following a flurry of positive developments and robust revenue growth that affirm growth metrics. For long-term investors, Predictive Technology is an interesting play with tremendous opportunity on the horizon.
We will be updating our subscribers as soon as we know more. For the latest updates on PRED, sign up below!
Disclosure: We have no position in PRED and have not been compensated for this article

 

[RapStar]

Predictive Technology Group Inc (OTCMKTS: PRED): A Buy On Improving Fundamentals

ByJim Bloom[/URL] Posted on August 13, 2019 [url]https://insiderfinancial.com/p...c-otcmktspred-improving-fundamentals/179266/# [/URL] [url]https://insiderfinancial.com/p...c-otcmktspred-improving-fundamentals/179266/#TWEET [/URL] [url]https://insiderfinancial.com/p...c-otcmktspred-improving-fundamentals/179266/#SARE [/URL] EMAIL [url]https://insiderfinancial.com/p...tspred-improving-fundamentals/179266/#respondCOMMENTS [/URL]Predictive Technology Group Inc (OTCMKTS: PRED) is an exciting bounce back play after a steep pullback from all-time highs. While the stock has taken a significant hit in recent months, one cannot dispute the company’s growth metrics and long-term prospects. The deep pullback presented an exciting buy opportunity as we discussed in our last article[/URL]. Many of our subscribers went long at $1.50 after getting our emails on PRED. PREDICTIVE TECHNOLOGY PRICE ANALYSIS The $1.50 is the immediate support level from where Predictive Technology is well supported for further upside action. The unveiling of a pharmacogenomic test panel targeting pain clinics is one of the catalysts fuelling the upward momentum. In addition, the company is fresh from inking a strategic partnership with the Preeclampsia Foundation as it moves to expand the study of genetic factors. Recent price action activity indicates that Predictive Technology might as well have hit bottom at the $1.50 level and due for a correction higher. A flurry of positive developments on the strengthening of the company’s product line should continue to trigger renewed investor interest in the stock.

Daily Chart PRED Above the $3 mark, the stock should make a run for the $5 a share mark, seen as the immediate resistance level standing in the way of further upside action. A close above the $3 a share level should bring to an end the bearish run that PRED succumbed in July. ABOUT PREDICTIVE TECHNOLOGY Predictive technology bills itself as a media technology company seeking to revolutionize patient care through predictive data analytics. The company is engaged in the development of gene-based diagnostics and therapeutics, targeting endometriosis, Scoliosis, and degenerative disc disease. CHRONIC PAIN OPPORTUNITY While Predictive Technology has shed a significant amount of market share after peaking in June, the future can only be bright given the progress made in developing gene-based diagnostics. The leader in data analytics for disease identification is fresh from unveiling game-changing pharmacogenomics test, poised to expand its footprint into the pain management market. The new pain test panel is designed to evaluate genetic factors that influence people’s response to medications. Predictive Technology, through its subsidiary Predictive Laboratories, has enrolled 350 patients as part of an Investigational Review Board approved clinical trials. PGxPLUS+test has the potential to be agama changer as a long term opioid therapy for chronic pain

[FONT=&]“The ability to effectively treat individuals in pain represents a significant market opportunity, and of even greater importance it serves an obligation of society to alleviate the current pain and suffering of an individual more safely and effectively,” said CEO Bradley Robinson.​

​

PREECLAMPSIA FOUNDATION PARTNERSHIP Separately, Predictive Technology has entered into a research collaboration with the Preeclampsia Foundation. As part of the partnership, the two are toe expand the study of genetic factors that trigger preeclampsia. The condition affects about 300,000 pregnancies every year, resulting in severe maternal and fetal outcomes. Organ failure, massive blood loss, and permanent disability are some of the outcomes associated with medical conditions. By studying the genetic factors associated with the condition, Predictive Technology and Preeclampsia hope to advance preeclampsia database. Predictive Laboratories will, in return, leverage the database to come up with a proprietary test for early detection, in women at risk of preeclampsia. ROBUST REVENUE GROWTH Recent developments underscore a company that has made huge strides in building a strong infrastructure for enhancing development and commercialization of proprietary genetic-based diagnostics. The future can only be bright, especially on the opening of a state of the art production laboratory and R&D facility. As it stands, Predictive Technology remains well positioned to meet production and sales needs of human cell and tissue products for regenerative medicine. A tenth consecutive quarter of revenue growth in the third quarter of 2019, underscores a company in a phase of robust growth. Revenue for the first nine months of fiscal 2019 exceeded the $30 million mark. Revenue growth stems from continued growth in sales volume as well as strong demand for human cell and tissue products. BOTTOM LINE True to the adage, buy low sell high. The steep pullback presented an opportunity to bet on Predictive Technology long-term prospects and growth metrics. We still believe PRED will see new highs later on this year. Market sentiments have started to pick up some steam following a flurry of positive developments and robust revenue growth that affirm growth metrics. For long-term investors, Predictive Technology is an interesting play with tremendous opportunity on the horizon. We will be updating our subscribers as soon as we know more. For the latest updates on PRED, sign up[/URL] below! Disclosure: We have no position in PRED and have not been compensated for this article [/FONT]

Thanks Bruce!

 

[RapStar]

Love it, thanks Bruce.

 

[brucefan]

 

[okie77]

Nice 25% bounceback today ��

 

[MattyMatt]

Beautiful day here today. Have a great weekend...